Biotechnology Stock News
Categories
- All
- Editor's Picks
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
GuruFocus Research Biotechnology
Maravai LifeSciences Holdings Inc (MRVI) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and Seizing Growth Opportunities
Despite a net loss, MRVI showcases strategic expansions and robust partnerships, setting the stage for future growth. 3 days ago
GuruFocus Research Biotechnology
CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic Partnerships and Promising Pipeline Progress
Explore key financial outcomes and clinical advancements as CytomX Therapeutics Inc (CTMX) navigates through Q1 2024 with robust partnerships and innovative cancer treatments. 3 days ago
GuruFocus Research Biotechnology
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and Strategic Advances Amid Challenges
Discover how Mirum Pharmaceuticals achieved a 137% increase in sales and navigated significant operational hurdles in the first quarter of 2024. 3 days ago
GuruFocus Research Biotechnology
Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Market Expansion
Explore key financial outcomes and strategic insights from Tarsus Pharmaceuticals' first quarter of 2024, highlighting significant sales growth and market penetration efforts. 3 days ago
GuruFocus Research Biotechnology
Arcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and Seizing Opportunities
Despite a widened net loss, Arcturus Therapeutics reports revenue growth and promising advancements in vaccine development. 3 days ago
GuruFocus Research Biotechnology
Arcus Biosciences Inc (RCUS) Q1 2024 Earnings Call Transcript Highlights: Strategic Partnerships and Robust Pipeline Progress
Discover how Arcus Biosciences Inc (RCUS) leverages strong financials and strategic collaborations to advance its oncology pipeline. 3 days ago
GuruFocus Research Biotechnology
Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic Progress Amid Financial Adjustments
Explore key financial outcomes and strategic updates from Relmada Therapeutics' first quarter of 2024, emphasizing advancements in clinical trials and operational efficiencies. 3 days ago
GuruFocus Research Biotechnology
Vanda Pharmaceuticals Inc (VNDA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and Seizing Opportunities
Amidst revenue declines and regulatory hurdles, Vanda Pharmaceuticals strategizes on new drug applications and market expansions. 3 days ago
GuruFocus Research Biotechnology
ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue Growth and Strategic Insights
ACADIA Pharmaceuticals showcases a 74% revenue surge and strategic expansions in its Q1 2024 earnings, underlining strong sales and future market plans. 3 days ago
GuruFocus Research Biotechnology
Aadi Bioscience Inc (AADI) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and Progressing Clinical Trials
Despite a dip in FYARRO sales and increased losses, AADI advances significant clinical trials and maintains a strong cash position. 3 days ago
GuruFocus Research Biotechnology
Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights and Financial Performance
Unveiling key financial results and strategic directions, including the impactful launch of VOWST and promising developments in SER-155. 3 days ago